AL-15469A for the Treatment of Bacterial Conjunctivitis

Alcon Research695 enrolled

Overview

The purpose of the study is to determine whether AL-15469A is safe and effective in the treatment of bacterial conjunctivitis.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

DOUBLE

Enrollment

695

Conditions

Bacterial Conjunctivitis

Interventions

Moxifloxacin Alternative Formulation Ophthalmic Solution 0.5%DRUG

1 drop into the conjunctival sac of both eyes 3 times a day for 3 days

Moxifloxacin hydrochloride ophthalmic solution 0.5% as baseDRUG

1 drop into the conjunctival sac of both eyes 3 times a day for 3 days

Eligibility

Sex: ALLMin age: 1 Month

Medical Language ↔ Plain English

Inclusion Criteria: * signs and symptoms of bacterial conjunctivitis * Other protocol-defined inclusion criteria may apply Exclusion Criteria: * under 1 mo. age * Other protocol-defined exclusion criteria may apply

Locations (1)

Contact Alcon for Trial Locations

Fort Worth, Texas, United States

Outcomes

Primary Outcomes

Clinical cure and microbiological success

Secondary Outcomes

Individual signs and symptoms of bacterial conjunctivitis at each visit

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.